Reit. Buy: Aquablation Gets Even Stronger Support in New AUA Guidelines for BPH

Research evidence excerpt

Reit. Buy: Aquablation Gets Even Stronger Support in New AUA Guidelines for BPH

Medical Supplies & Devices

Procept BioRobotics Corp

TD SECURITIES (USA) LLC QUICK TAKE: COMPANY UPDATE

May 14, 2026

Price: $25.70 (05/13/2026) Reit. Buy: Aquablation Gets Even Stronger

Price Target: $34.00 Support in New AUA Guidelines for BPH

BUY (1)

ESG SCORE: 64/100

Joshua Jennings, M.D. THE TD COWEN INSIGHT

646 562 1333

New AUA guidelines for BPH offer increased support for Aquablation vs the prior guidelines

joshua.jennings@tdsecurities.com

they replace. Specifically the 2026 guidelines strengthen the recommendation for Aquablation

Colin Clark in prostates 30–80 mL and additionally state that Aquablation can be used in larger prostates

646 562 1441 80–150 mL, which is entirely new. We think these upgrades reflect growing recognition of

colin.clark@tdsecurities.com

Aquablation's data-proven merits.

John Rusch, CFA

646 562 1324 Reiterate Buy: Latest AUA Guidelines Strengthen Support for Aquablation

john.rusch@tdsecurities.com

The American Urological Association has published new guidelines for the management of

Key Data lower urinary tract symptoms attributed to benign prostatic hyperplasia. The latest guidelines,

Symbol NASDAQ: PRCT

which update the AUA's BPH guidelines from 2021-23, provide greater support for Aquablation

Market Cap $1.5B than previously, which we think reflects the growing recognition of Aquablation's data-proven

merits and should help drive the therapy's continued commercial adoption.

Specifically, the latest 2026 guidelines (1) strengthen the recommendation for Aquablation

in prostates 30–80 mL and (2) additionally state that Aquablation may be offered in larger

prostates 80–150 mL, which is entirely new. The chart on page 2 compares the new guidelines